How should tigecycline be administered intravenously, including dosing, dilution, and infusion rate for adults and pediatric patients?

How to Administer Tigecycline IV

For adults, administer tigecycline as a 100 mg IV loading dose followed by 50 mg IV every 12 hours, infused over 30-60 minutes; for pediatric patients 8-11 years use 1.2 mg/kg (max 50 mg) every 12 hours, and for ages 12-17 years use 50 mg every 12 hours, though pediatric use should be avoided unless no alternatives exist. 1

Adult Dosing

Standard Dosing

• Loading dose: 100 mg IV
• Maintenance dose: 50 mg IV every 12 hours
• Infusion time: 30-60 minutes 1

Hepatic Impairment Adjustments

• Child-Pugh A and B: No dose adjustment needed
• Child-Pugh C (severe): 100 mg loading dose, then reduce maintenance to 25 mg every 12 hours 1, 2

The reduction in severe hepatic impairment is critical—pharmacokinetic data show tigecycline clearance drops to 13.5 ± 2.7 L/h in Child-Pugh C patients compared to 29.8 ± 11.3 L/h in healthy subjects 2.

Renal Impairment

No dose adjustment required regardless of renal function 1

High-Dose Regimens (Off-Label)

For critically ill patients with multidrug-resistant organisms, particularly in HAP/VAP:

• Loading dose: 200 mg IV
• Maintenance dose: 100 mg IV every 12 hours 3, 4

This high-dose approach is supported by evidence showing it's the only independent predictor of clinical cure in VAP patients 3, though it should be reserved for severe infections with limited alternatives.

Pediatric Dosing

Critical Warning

Avoid tigecycline in pediatric patients unless no alternative antibacterial drugs are available due to increased mortality risk observed in adults 1. Pediatric dosing regimens have not been validated for safety and efficacy 1.

Suggested Doses (When No Alternatives Exist)

• Ages 8-11 years: 1.2 mg/kg IV every 12 hours (maximum 50 mg per dose) 5, 1, 6
• Ages 12-17 years: 50 mg IV every 12 hours 5, 1
• Infusion time: 30-60 minutes

These doses are based on pharmacokinetic modeling showing they achieve similar exposures to adults receiving 50 mg every 12 hours 6. No data exist for pediatric patients with hepatic impairment 1.

Preparation and Administration

Reconstitution Steps

1. Add 5.3 mL of compatible diluent to each vial (0.9% NaCl, 5% Dextrose, or Lactated Ringer's) to achieve 10 mg/mL concentration
2. Gently swirl until dissolved (do not shake vigorously)
3. Withdraw 5 mL of reconstituted solution (equivalent to 50 mg)
4. Add to 100 mL IV bag for final infusion 1

Key Preparation Details

• Each vial contains 6% overage, so 5 mL = 50 mg drug
• For 100 mg dose: reconstitute two vials
• For 50 mg dose: reconstitute one vial
• Maximum concentration in IV bag: 1 mg/mL 1

Visual Inspection

• Acceptable color: Yellow to orange
• Discard if: Green, black, or contains particulate matter 1

Storage After Reconstitution

Room Temperature (≤25°C/77°F)

• Total time: Up to 24 hours
  • Up to 6 hours in vial
  • Remaining time in IV bag
• If >25°C: Use immediately 1

Refrigerated (2-8°C/36-46°F)

• Up to 48 hours when mixed with 0.9% NaCl or 5% Dextrose (requires immediate transfer to IV bag after reconstitution) 1

IV Line Compatibility

Compatible Diluents

• 0.9% Sodium Chloride
• 5% Dextrose
• Lactated Ringer's 1

Y-Site Compatible Medications

When using 0.9% NaCl or 5% Dextrose as carrier:

• Amikacin, gentamicin, tobramycin
• Dobutamine, dopamine, norepinephrine
• Morphine, lidocaine
• Metoclopramide, ranitidine
• Potassium chloride, theophylline
• Propofol (with 5% Dextrose only) 1

Line Flushing

Flush line before and after tigecycline with compatible solution (0.9% NaCl, 5% Dextrose, or Lactated Ringer's) when using sequential infusions 1

Treatment Duration

• Complicated skin/skin structure infections: 5-14 days
• Complicated intra-abdominal infections: 5-14 days 5
• Community-acquired pneumonia: 7-14 days 1

Duration should be guided by infection severity, site, and clinical/bacteriological response 1.

Critical Caveats

Mortality Warning

Meta-analysis shows 0.6% increased all-cause mortality with tigecycline versus comparators (95% CI 0.1-1.2). Reserve for situations when alternatives are unsuitable 1.

Not Recommended For

• Diabetic foot infections (failed non-inferiority trial)
• Hospital-acquired/ventilator-associated pneumonia (increased mortality and decreased efficacy in comparative trials) 1
• Complicated UTI due to CRE (inferior to aminoglycosides with moderate certainty of evidence) 3

Common Adverse Effects

Nausea and vomiting are class effects—occurred in 50-65% of pediatric patients at higher doses 6, 7. Consider antiemetic prophylaxis, particularly in children.